The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Discovery and development of anticancer aptamers
Abstract
Aptamers, also termed as decoys or “chemical antibodies,” represent an emerging class of therapeutics. They are short DNA or RNA oligonucleotides or peptides that assume a specific and stable three-dimensional shape in vivo, thereby providing specific tight binding to protein targets. In some cases and as opposed to antisense oligonucleotides, effects can be mediated against extracellular targets, thereby preventing a need for intracellular transportation. The first aptamer approved for use in man is a RNA-based molecule (Macugen, pegaptanib) that is administered locally (intravitreally) to treat age-related macular degeneration by targeting vascular endothelial growth factor. The most advanced aptamer in the cancer setting is AS1411, formerly known as AGRO100, which is being administered systemically in clinical trials. AS1411 is a 26-mer unmodified guanosine-rich oligonucleotide, which induces growth inhibition in vitro, and has shown activity against human tumor xenografts in vivo. The mechanism underlying its antiproliferative effects in cancer cells seems to involve initial binding to cell surface nucleolin and internalization, leading to an inhibition of DNA replication. In contrast to other unmodified oligonucleotides, AS1411 is relatively stable in serum-containing medium, probably as a result of the formation of dimers and a quartet structure. In a dose escalation phase I study in patients with advanced solid tumors, doses up to 10 mg/kg/d (using a four or seven continuous infusion regime) have been studied. Promising signs of activity have been reported (multiple cases of stable disease and one near complete response in a patient with renal cancer) in the absence of any significant adverse effects. Further trials are ongoing in renal and non–small cell lung cancers. In preclinical studies, additional aptamers have been described against several cancer targets, such as tenascin-C, the transcription factor signal transducer and activator of transcription 3, and antiapoptotic and Ku proteins. [Mol Cancer Ther 2006;5(12):2957–62]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
DIVERSITY OF OLIGONUCLEOTIDE FUNCTIONS
Gold, L., Polisky, B., Uhlenbeck, O., & Yarus, M. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003555 · Cited by 805
Daniels, D. A., Chen, H., Hicke, B. J., Swiderek, K. M., & Gold, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2136683100 · Cited by 567
Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels
Christian, S., Pilch, J., Akerman, M. E., Porkka, K., Laakkonen, P., & Ruoslahti, E. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200304132 · Cited by 497
Molecular dissection of nucleolin's role in growth and cell proliferation: new insights
Srivastava, M., & Pollard, H. B. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1911 · Cited by 494
THE EYETECH STUDY GROUP (2002) · Retina · doi:10.1097/00006982-200204000-00002 · Cited by 415
Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding
Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., & Miller, D. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26369 · Cited by 407
Biophysical and biological properties of quadruplex oligodeoxyribonucleotides
Dapic, V. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg316 · Cited by 397
Regulatory pathways governing HIV-1 replication
Cullen, B. R., & Greene, W. C. (1989) · Cell · doi:10.1016/0092-8674(89)90420-0 · Cited by 396
Cited by
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
Veiseh, O., Gunn, J. W., & Zhang, M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.002 · Cited by 1,832
Development of DNA aptamers using Cell-SELEX
Sefah, K., Shangguan, D., Xiong, X., O'Donoghue, M. B., & Tan, W. (2010) · Nature Protocols · doi:10.1038/nprot.2010.66 · Cited by 918
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Aptamers and Their Biological Applications
Song, K.-M., Lee, S., & Ban, C. (2012) · Sensors · doi:10.3390/s120100612 · Cited by 821
Aptamers Generated from Cell-SELEX for Molecular Medicine: A Chemical Biology Approach
Fang, X., & Tan, W. (2010) · Accounts of Chemical Research · doi:10.1021/ar900101s · Cited by 747
Metadata
- Authors
- Ireson, C. R., & Kelland, L. R.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-12-01
- Volume
- 5
- Issue
- 12
- Pages
- 2957-2962
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W1985290031
- Cited by
- 481
- References
- 28
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and development of anticancer aptamers. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0172
- The paper
- Ireson, C. R., & Kelland, L. R. (2006). Discovery and development of anticancer aptamers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0172
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.